Ipamorelin tends to be the go-to for performance-driven goals, like cutting fat, preserving muscle, and recovering faster
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
doi: 10.1016/j.jare.2021.04.001 121 ZaccariaE.KlaassenT.AlleleynA
BPC-157 is the ultra-concentrated version of that protein, and it harnesses its vast protective power
Trials summarized by Leidy and colleagues show that people on higher-protein, calorie-restricted diets generally lose more fat mass , preserve more lean mass , and report higher fullness than people on lower-protein diets